Driehaus Micro Cap Growth holds a quantitatively derived Bronze Morningstar Medalist Rating. The rating reflects that it has scored better than the norm on factors Morningstar research associates with future outperformance relative to category peers.
Driehaus Micro Cap Growth Fund DMCRX
- NAV / 1-Day Return 18.47 / +0.33 %
- Total Assets 522.2M
-
Adj. Expense Ratio
1.340%
- Expense Ratio 1.300%
- Distribution Fee Level High
- Share Class Type No Load
- Category Small Growth
- Investment Style Small Growth
- Min. Initial Investment 10,000
- Status Limited
- TTM Yield 0.22%
- Turnover 142%
USD | NAV as of Oct 02, 2026 | 1-Day Return as of Oct 02, 2026, 12:22 AM GMT+0
Morningstar’s Analysis DMCRX
Will DMCRX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 17.9
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Northern Institutional US Govt Sel | 3.54 | 19M | Cash and Equivalents |
Definium Therapeutics Inc Ordinary Shares | 2.53 | 13M | Healthcare |
Spyre Therapeutics Inc | 2.48 | 13M | Healthcare |
Praxis Precision Medicines Inc Ordinary Shares | 2.13 | 11M | Healthcare |
nLight Inc | 1.75 | 9M | Technology |
Kiniksa Pharmaceuticals International PLC Class A | 1.58 | 8M | Healthcare |
Bandwidth Inc Class A | 1.55 | 8M | Technology |
Lindblad Expeditions Holdings Inc | 1.49 | 8M | Consumer Cyclical |
Xometry Inc Ordinary Shares - Class A | 1.48 | 8M | Industrials |
MBX Biosciences Inc | 1.47 | 8M | Healthcare |